Navigation Links
RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay


Gene arrays can be used to simultaneously measure the expression levels of thousands of genes in a single experiment. One limitation of this technology is that large amounts of RNA may be required for each array hybridization experiment -- typically 10 g of total RNA. This becomes problematic when working with limited samples, such as small biopsies, mRNA-poor cells and tissues, primary cultured cells, and laser capture microdissection (LCM) samples, and, in this example, cells selected and collected by flow cytometry. RNA amplification is needed to perform array analysis on these limited samples.


Goodrum FD, Jordan CT, High K & Shenk T. (2002) Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor Cells: A model for latency. Proc Natl Acad Sci (USA) 99 (25): 16255-16260.

Ambion's MessageAmp aRNA Amplification Kit is based on an antisense RNA (aRNA) amplification procedure first described by Van Gelder and Eberwine (1). The protocol involves a series of enzymatic reactions resulting in linear amplification of exceedingly small amounts of RNA for use in array analysis. Here this method is applied to amplify RNA from a small number of human cytomegalovirus (HCMV) infected CD34+ progenitor cells to compare the expression pattern of these infected cells, an in vitro model, with that of normal fibroblasts and to correlate their expression with in vivo infected bone marrow cells.

HCMV is a ubiquitous herpes virus found in 80% of the population where it is maintained in a latent form. Infection of healthy normal individuals by HCMV is usually harmless, but reactivation of the latent virus in immune compromised individuals can be life threatening. The latent viral replication can be activated in a subset of bone marrow cells. Unfortunately, it is currently not possible to work with these cells in culture nor has there been an in vitro model for the study of the latent virus (3).

Recently, Goodrum et al. (2) used microarray analyses to establish the role of infected primary CD34+ haemotopoeitic progenitors grown above a murine stromal AFT024 monolayer as a potential in vitro model system to study HCMV latency. For this study, HCMV cDNA arrays comprised of PCR products from 222 known ORF's for the AD169 and Toledo strains of HCMV (2,4) were tested with cDNA probes made from primary human fibroblasts or human CD34+ progenitor cells infected in vitro with HCMV. RNA was isolated from 10,000-20,000 infected CD34+ cells and then amplified using Ambion's MessageAmp aRNA Amplification Kit. For the human fibroblasts, total RNA was isolated and DNase I treated with Ambion's DNA-free Kit. Poly(A) RNA selection was carried out using the Ambion MicroPoly(A)Pure Kit. cDNA probes were made by reverse transcription of the mRNA (for fibroblasts*) or amplified RNA (for CD34+ cells).

While all of the genes expressed in an active viral infection were observed with the fibroblasts during the complete course of viral replication (Figure 1, Panel A), the CD34+ cells showed expression of only a subset of viral genes during the 8 day time course following infection (Figure 1, Panel B). (Reactivation of viral replication was achieved in the CD34+ cells by
co-culturing with fibroblasts.) Analysis of the gene expression microarray data obtained from the latent CD34+ cells was validated by RT-PCR analysis. Thus the subset of genes expressed in the absence of active viral replication could be indicative of the subset of genes that are necessary for latent infection.

Figure 1. Comparison of HCMV Gene Expression in CD34+ and Primary Human Fibroblasts. (A) HCMV arrays were analyzed using cDNA probes made against primary human fibroblasts. (B) HCMV arrays were analyzed using cDNA probes against CD34+ cells. Each of the arrays has viral sequences spotted in triplicate, the bottom right most triplicate is spotted with cellular housekeeping genes as controls.


*Note: For the human fibroblast RNA, the gene expression profile did not vary significantly between amplified vs. unamplified samples.

We would like to thank Dr. Felicia Goodrum for pr oviding the data and for critical reading of the manuscript. Dr. Goodrum is a postdoctoral fellow in Dr. Thomas Shenk's laboratory at Princeton University.


back to top


Ordering Information
Cat# Product Name Size 1750 MessageAmp aRNA Kit 20 rxns
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater
2. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
3. Simple Purification of DNA from Plasmid Minipreps, PCR Amplifications and Agarose Gels
4. Greater Amplification Specificity with New Hot Start PCR Enzyme
5. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
6. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
7. Improve Amplification Specificity with Hot Start PCR Enzyme
8. Amplification of the amoA Gene of Nitrosococcus oceani Bacteria Using Eppendorf MasterTaq
9. Amplification of Mouse cDNAs for Microarrays Using the Eppendorf MasterTaq Kit
10. Optimizing the Direct Amplification of Missing cDNA 5 Ends Using the Eppendorf Mastercycler gradient
11. Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):